Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany
Table 1
Patient and tumor characteristics of patients () with advanced or metastatic esophagogastric adenocarcinoma documented in Therapiemonitor 2006–2013. CT = chemotherapy; KPS = Karnofsky performance status; TT = targeted therapy.
Total number of patients 2006–2009 (%)
Total number of patients 2010 (%)
Total number of patients II.-III. quarter 2011 (%)
Total number of patients III. quarter 2012 (%)
Total number of patients III. quarter 2013 (%)
Total number of patients receiving palliative 1st-line CT/TT ()
1,058
754
314
325
357
Gender
Male; (%)
674 (63.8)
473 (62.7)
205 (65.3)
200 (61.5)
226 (63.3)
Female; (%)
383 (36.2)
281 (37.3)
109 (34.7)
125 (38.5)
131 (36.7)
Age; median (years)
67
67
66
65
65
Range (years)
24–100
24–90
29–96
20–86
19–88
Patients aged < 65 years (%)
44.7
42.3
46.8
46.9
49.7
Patients with KPS ≥ 80% in 1st-line treatment (%)
72.9
72.6
70.7
67.8
66.6
Patients with initial diagnosis of carcinoma in stage IV (%)
69.8
70.0
65.0
67.7
74.2
Histology
Signet cell cancer (%)
14.5
24.1
24.2
12.3
26.9
Undifferentiated cancer (G3) (%)
43.5
46.9
43.6
44.0
45.7
Metastatic sites
Liver (%)
50.1
62.0
59.5
61.8
61.6
Peritoneum (%)
43.2
45.7
47.3
47.8
55.7
Lung (%)
17.1
24.9
26.7
20.5
20.4
Bone (%)
8.5
10.0
13.8
11.8
8.4
Patients participating in clinical trials on 1st-line chemotherapy (%)
10.1
7.8
4.8
1.5
0.6
Treatment institution
University hospital
16.9
25.2
26.8
17.8
23.9
Other hospitals
59.7
52.4
53.4
60.3
42.4
Oncology practice
28.0
29.6
35.1
33.2
39.3
Unknown
—
—
—
0.6
0.6
Insurance status
Statutory insurance (%)
91.7
88.8
87.6
88.9
84.3
Private insurance (%)
8.3
11.2
12.4
11.1
15.7
Note. Information on gender is missing in one patient. Multiple answers were permitted. Information is missing in one patient 2013. Other than statutory insurance, in 2012 and 2012 the KPS was placed in the last form “Therapiestatus” and changed to KPS in the last therapy decision.
